ARTICLE | Product Development
Sanofi sets MS submission goals for Principia-partnered Btk inhibitor, details Phase II data
April 24, 2020 1:17 AM UTC
Updated on Apr 24, 2020 at 1:42 AM UTC
Two months after Sanofi announced plans to send its oral multiple sclerosis therapy into Phase III testing, the company unveiled the detailed Phase IIb data from recurring MS patients driving the Btk inhibitor’s clinical advancement.
On a conference call Thursday, Sanofi (Euronext:SAN; NASDAQ:SNY) also revealed marketing application milestones: a 2024 submission for relapsing MS and 2025 submissions for primary progressing MS (PPMS) and non-relapsing secondary progressive MS (NR-SPMS)...
BCIQ Target Profiles